Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: Final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry - 26/05/21
, Iván Olier, PhD b, Gisela Feltes, MD c, María C. Viana-Llamas, MD d, Charbel Maroun-Eid, MD e, Rodolfo Romero, MD, PhD f, Inmaculada Fernández-Rozas, MD g, Aitor Uribarri, MD, PhD h, Victor M. Becerra-Muñoz, MD i, Emilio Alfonso-Rodriguez, MD j, Marcos García-Aguado, MD k, Javier Elola, MD, PhD l, Alex Castro-Mejía, MD m, Martino Pepe, MD, PhD n, Juan Fortunato Garcia-Prieto, MD o, Adelina Gonzalez, MD p, Fabrizio Ugo, MD, PhD q, Enrico Cerrato, MD, PhD r, Elvira Bondia, MD s, Sergio Raposeiras-Roubin, MD, PhD t, Jorge L. Jativa Mendez, MD, PhD u, Carolina Espejo, MD v, Álvaro López-Masjuan, MD w, Francisco Marin, MD, PhD x, Javier López-Pais, MD y, Mohammad Abumayyaleh, MD, PhD z, Miguel Corbi-Pascual, MD, PhD aa, Christoph Liebetrau, MD, PhD bb, Harish Ramakrishna, MD, FACC, FESC cc, Vicente Estrada, MD, PhD a, Carlos Macaya, MD, PhD a, Antonio Fernandez-Ortiz, MD, PhD aOn behalf of
HOPE COVID-19 Investigators (Cols Appendix)
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
ABSTRACT |
Background |
The use of Renin-Angiotensin system inhibitors (RASi) in patients with coronavirus disease 2019 (COVID-19) has been questioned because both share a target receptor site.
Methods |
HOPE-COVID-19 (NCT04334291) is an international investigator-initiated registry. Patients are eligible when discharged after an in-hospital stay with COVID-19, dead or alive. Here, we analyze the impact of previous and continued in-hospital treatment with RASi in all-cause mortality and the development of in-stay complications.
Results |
We included 6503 patients, over 18 years, from Spain and Italy with data on their RASi status. Of those, 36.8% were receiving any RASi before admission. RASi patients were older, more frequently male, with more comorbidities and frailer. Their probability of death and ICU admission was higher. However, after adjustment, these differences disappeared. Regarding RASi in-hospital use, those who continued the treatment were younger, with balanced comorbidities but with less severe COVID19. Raw mortality and secondary events were less frequent in RASi. After adjustment, patients receiving RASi still presented significantly better outcomes, with less mortality, ICU admissions, respiratory insufficiency, need for mechanical ventilation or prone, sepsis, SIRS and renal failure (p<0.05 for all). However, we did not find differences regarding the hospital use of RASi and the development of heart failure.
Conclusion |
RASi historic use, at admission, is not related to an adjusted worse prognosis in hospitalized COVID-19 patients, although it points out a high-risk population. In this setting, the in-hospital prescription of RASi is associated with improved survival and fewer short-term complications.
Le texte complet de cet article est disponible en PDF.Plan
| Trial Numbers: NCT04334291/ EUPAS34399. |
Vol 237
P. 104-115 - juillet 2021 Retour au numéro
Article précédent
- Effect of a smartphone-based intervention on secondary prevention medication prescriptions after coronary artery bypass graft surgery: The MISSION-1 randomized controlled trial
- Jianyu Qu, Junzhe Du, Chenfei Rao, Sipeng Chen, Dachuan Gu, Jing Li, Heng Zhang, Yan Zhao, Shengshou Hu, Zhe Zheng, for the MISSION-1 Collaborative Group
- Sex disparities in patients with symptomatic severe aortic stenosis
- Angela Lowenstern, Paige Sheridan, Tracy Y. Wang, Isabel Boero, Sreekanth Vemulapalli, Vinod H. Thourani, Martin B. Leon, Eric D. Peterson, J. Matthew Brennan
Bienvenue sur EM-consulte, la référence des professionnels de santé.